MSTN and Charcot-Marie-Tooth disease type 1A: Meanwhile, clinical trials including ascorbic acid58,59 (NCT00484510), a myostatin inhibitor60 and progesterone receptor antagonist (NCT02600286) have failed to identify clinical benefits for CMT1A patients.